Identifying and addressing barriers to insulin acceptance and adherence in patients with type 2 diabetes mellitus

Journal of the American Osteopathic Association

Volumn 113, Issue 4 SUPPL.2, 2013, Pages

  Petznick, Allison M ^a  

^a Firelands Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ATTITUDE TO HEALTH; DIABETES MELLITUS, TYPE 2; HUMAN; MEDICATION COMPLIANCE; PATIENT ATTITUDE; PATIENT EDUCATION; SELF CARE; ARTICLE; NON INSULIN DEPENDENT DIABETES MELLITUS;

ATTITUDE TO HEALTH; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MEDICATION ADHERENCE; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT EDUCATION AS TOPIC; SELF CARE;

EID: 84876362784     PISSN: 00986151     EISSN: 19451997     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease Control and Prevention; 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed February 13, 2013.
2. Centers for Disease Control and Prevention. Increasing prevalence of diagnosed diabetes-United States and Puerto Rico, 1995-2010. MMWR Morb Mortal Wkly Rep. 2012;61(45):918-921.
3. Centers for Disease Control and Prevention. County level estimates of diagnosed diabetes-U.S. maps: 2009 age-adjusted estimates of the percentage of adults with diagnosed diabetes. http://apps.nccd.cdc.gov/DDT_STRS2/NationalDiabetesPrevalenceEstimates.aspx?mode=DBT. Accessed January 15, 2013.
4. Cunningham SA, Riosmena F, Wang J, Boyle JP, Rolka DB, Geiss LS. Decreases in diabetesfree life expectancy in the U.S. and the role of obesity. Diabetes Care. 2011;34(10):2225-2230.
5. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44(11):1249-1258.
6. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102-110
7. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia. 2004(1);47:31-39.
8. Bergenstal RM, Kendall DM, Franz MJ, Rubenstein AH. Management of type 2 diabetes: a systematic approach to meeting the standards of care. II: oral agents, insulin, and management of complications. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 4th ed. Philadelphia, PA: WB Saunders; 2001:821-835.
9. United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
11. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36(suppl 1):S11-S66.
12. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
13. Gerstein HC, Miller ME, Byington RP, et al. for the Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
14. Duckworth W, Abraira C, Moritz T, et al; for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
15. Patel A, MacMahon S, Chalmers J, et al; for the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
16. Handelsman Y, Mechanick JI, Blonde L, et al; for the AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17(suppl 2):S1-S53.
17. Committee on Quality of Health Care in America, Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001:40.
18. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
19. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156(3):218-231.
20. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
21. Garber AJ. Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus. J Am Osteopath Assoc. 2011;111(7 suppl 5):S20-S30.
22. Freeman JS. Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus. J Am Osteopath Assoc. 2012;112(1 suppl 1):S2-S6.
23. Best JD, Drury PL, Davis TM, et al. Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. Diabetes Care. 2012;35(5):1165-1170.
24. Rolla AR. What about insulin as an immediate first step for type 2 diabetes? Diabetes Obes Metab. 2009;11(suppl 5):S19-S22.
25. Tibaldi JM. The future of insulin therapy for patients with type 2 diabetes mellitus. J Am Osteopath Assoc. 2013;113(4 suppl 2):S29-S39.
26. Peyrot M, Rubin RR, Lauritzen T, et al; For the International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-2679.
27. Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes. 2010;4(suppl 1):S11-S18.
28. Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications. 2007;21(4):220-226.
29. Polonsky WH, Hajos TR, Dain MP, Snoek FJ. Are patients with type 2 diabetes reluctant to start insulin therapy? an examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin. 2011;27(6):1169-1174.
30. Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35(6):1279-1284.
31. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-1841.
32. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(suppl 5A):S27-S34.
33. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240-245.
34. Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ. 2009;35(6):1014-1022
35. Lloyd A, Nafees B, Barnett AH, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus. Clin Ther. 2011;33(9):1258-1267.
36. Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33(4):733-735.
37. Unger J. Comparing the efficacy, safety, and utility of intensive insulin algorithms for a primary care practice. Diabetes Ther. 2011;2(1):40-50.
38. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32(suppl 1):S9-S18.
39. Freeman JS. Insulin analog therapy: improving the match with physiologic insulin secretion. J Am Osteopath Assoc. 2009;109(1):26-36.
40. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352(2):174-183.
41. Monami M, Marchionni N, Mannucci E. Longacting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81(2):184-189.
42. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
43. Peyrot M, Rubin RR. Behavioral and psychosocial interventions in diabetes: a conceptual review. Diabetes Care. 2007;30(10):2433-2440.